2014 European Guideline on the management of sexually acquired reactive arthritis

International Journal of STD and AIDS

Volumn 25, Issue 13, 2014, Pages 901-912

  Carlin, E M ^a   Ziza, J M ^b   Keat, A ^c   Janier, M ^d  

^a SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^c EALING HOSPITAL NHS TRUST   (United Kingdom)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; AZITHROMYCIN; CIPROFLOXACIN; DOXYCYCLINE; ETANERCEPT; GOLD SALT; INFLIXIMAB; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; ANTIINFECTIVE AGENT; ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE PHASE RESPONSE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTHRITIS; ARTICLE; BLOOD CELL COUNT; BLOOD CULTURE; BREAST FEEDING; CHLAMYDIA TRACHOMATIS; CHRONICITY; CLINICAL FEATURE; ECHOCARDIOGRAPHY; ENTHESITIS; ENTHESOPATHY; EYE INJURY; FAMILY HISTORY; FATIGUE; FECES CULTURE; FOLLOW UP; GENITAL TRACT INFECTION; HEART INJURY; HEMATURIA; HUMAN; INFLAMMATORY PAIN; JOINT BIOPSY; MUCOSA; NEISSERIA GONORRHOEAE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOGENESIS; PRACTICE GUIDELINE; PREGNANCY; PROTEINURIA; PSORIASIS; PYURIA; REACTIVE ARTHRITIS; REST; SEXUAL INTERCOURSE; SEXUALLY ACQUIRED REACTIVE ARTHRITIS; SEXUALLY TRANSMITTED DISEASE; SYNOVECTOMY; SYNOVIAL FLUID; TENOSYNOVITIS; UREAPLASMA UREALYTICUM; URINALYSIS; ARTHRITIS, REACTIVE; COMPLICATION; DISEASE MANAGEMENT; EUROPE; SEXUALLY TRANSMITTED DISEASES, BACTERIAL;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, REACTIVE; DISEASE MANAGEMENT; EUROPE; HUMANS; PRACTICE GUIDELINES AS TOPIC; SEXUALLY TRANSMITTED DISEASES, BACTERIAL;

EID: 84908501663     PISSN: 09564624     EISSN: 17581052     Source Type: Journal    
DOI: 10.1177/0956462414540617     Document Type: Article

References (132)

1. Leirisalo-Repo M,Repo HRheumatology. 5th ed. Philadelphia: Mosby Elsevier, 2011. Section 8: Infection-related rheumatic diseases, vol. 110, pp.1113–1120.Hochberg MCSilman AJSmolen JSWeinblatt MEWeisman MH, ed. Philadelphia: Mosby Elsevier; 2011:
2. Hannu T,Mattila L,Siitonen A, et al.Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study.Ann Rheum Dis. 2005;64:594-598
3. Keat A.Reiter’s syndrome and reactive arthritis in perspective.N Engl J Med. 1983;309:1606-1615
4. Csonka GW.The course of Reiter’s Syndrome.Br Med J. 1958;1:1088-1090
5. Keat AC,Maini RN,Nkwazi GC, et al.Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis.Br Med J. 1978;1:605-607
6. Rich E,Hook EW,Alarcón GS, et al.Reactive arthritis in patients attending an urban sexually transmitted diseases clinic.Arthr Rheum. 1996;39:1172-1177
7. Hamdulay SS,Glynne SJ,Keat A.When is arthritis reactive?.Postgrad Med J. 2006;82:446-453
8. Stein CM,Davis P.Arthritis associated with HIV infection in Zimbabwe.J Rheumatol. 1996;23:506-511
9. Clark MR,Solinger AM,Hochberg MC.Human immunodeficiency virus infection is not associated with Reiter’s syndrome. Data from three large cohort studies.Rheum Dis Clin North Am. 1992;18:267-276
10. Mijiyawa M,Oniankitan O,Khan MA.Spondyloarthropathies in sub-Saharan Africa.Curr Opin Rheumatol. 2000;12:281-286
11. Keat AC,Thomas BJ,Taylor-Robinson D, et al.Evidence of Chlamydia trachomatis infection in sexually acquired reactive arthritis.Ann Rheum Dis. 1980;39:431-437
12. Martin DH,Pollock S,Kuo C-C, et al.Chlamydia trachomatis infections in men with Reiter’s syndrome.Ann Intern Med. 1984;100:207-213
13. Keat A,Thomas B,Dixey J, et al.Chlamydia trachomatis and reactive arthritis: the missing link.Lancet. 1987;1:72-4
14. Kousa M,Saikku P,Richmond S, et al.Frequent association of chlamydial infection with Reiter’s syndrome.Sex Transm Dis. 1978;5:57-61
15. Colmegna I,Cuchacovich R,Espinoza LR.HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.Clin Microbiol Rev. 2004;17:348-369
16. Flores D,Marquez J,Garza M, et al.Reactive arthritis: newer developments.Rheum Dis Clin N Am. 2003;29:37-59
17. Rosenthal L,Olhagen B,Ek S.Aseptic arthritis after gonorrhoea.Ann Rheum Dis. 1980;39:141-146
18. Leirisalo M,Skylv G,Kousa M, et al.Follow-up study on patients with Reiter’s disease and reactive arthritis with special reference to HLA-B27.Arthr Rheum. 1982;25:249-259
19. Kousa M.Clinical observations on Reiter’s disease with special reference to the venereal and non-venereal aetiology.Acta Derm Venereol. 1978;58:5-36
20. Csonka GW.Clinical aspects of Reiter’s syndrome.Ann Rheum Dis. 1979;38:4-7
21. Schaeverbeke T,Renaudin H,Vernhes JP, et al.Ureaplasma urealyticum and reactive arthritis.Clin Rheumatol. 1995;14:252-252
22. Horowitz S,Horowitz J,Taylor-Robinson D, et al.Ureaplasma urealyticum in Reiter’s syndrome.J Rheumatol. 1994;21:877-882
23. Schumacher HR,Magge S,Cherian PV, et al.Light and electron microscopic studies on the synovial membrane in Reiter’s syndrome: immunocytochemical identification of chlamydial antigen in patients with early disease.Arthr Rheum. 1988;31:937-946
24. Taylor-Robinson D,Gilroy CB,Thomas BJ, et al.Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction.Lancet. 1992;340:81-82
25. Rahman MU,Cheema MA,Schumacher HR, et al.Molecular evidence for the presence of chlamydia in the synovium of patients with Reiter’s syndrome.Arthr Rheum. 1992;35:521-529
26. Bas S,Griffais R,Kvein TK, et al.Amplification of plasmid and chromosome chlamydia DNA in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies.Arthr Rheum. 1995;38:1005-1013
27. Branigan PJ,Gérard HC,Hudson AP, et al.Comparison of synovial tissue and synovial fluid as the source of nucleic acids for detection of Chlamydia trachomatis by polymerase chain reaction.Arthr Rheum. 1996;39:1740-1746
28. Li F,Bulbul R,Schumacher HR, et al.Molecular detection of bacterial DNA in venereal-associated arthritis.Arthr Rheum. 1996;39:950-958
29. Nikkari S,Puolakkainen M,Yli-Kerttula U, et al.Ligase chain reaction in detection of chlamydia DNA in synovial fluid cells.Br J Rheumatol. 1997;36:763-765
30. Vittecoq O,Schaeverbeke T,Favre S, et al.Molecular diagnosis of Ureaplasma urealyticum in an immunocompetent patient with destructive reactive polyarthritis.Arthr Rheum. 1997;40:2084-2089
31. Tully JG,Rose DL,Baseman JB, et al.Mycoplasma pneumoniae and Mycoplasma genitalium mixture in synovial fluid isolate.J Clin Microbiol. 1995;33:1851-1855
32. Gérard HC,Branigan PJ,Schumacher HR,Jr, et al.Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter’s syndrome are viable but show aberrant gene expression.J Rheumatol. 1998;25:734-742
33. Rihl M,Klos A,Köhler L, et al.Reactive arthritis.Best Practice Res Clin Rheumatol. 2006;20:1119-1137
34. Gerard HC,Whittum-Hudson JA,Carter JD, et al.The pathogenic role of Chlamydia in spondyloarthritis.Curr Opin Rheumatol. 2010;22:363-367
35. Keat AC,Maini RN,Pegrum GD, et al.The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis.QJM. 1979;48:323-342
36. Carter JD.Treating reactive arthritis: insights for the clinician.Ther Adv Musculoskel Dis. 2010;2:45-54
37. Csonka GW.Long-term follow-up and prognosis of Reiter’s syndrome.Ann Rheum Dis. 1979;38:24-28
38. Good AE.Reiter’s syndrome: long-term follow-up in relation to development of ankylosing spondylitis.Ann Rheum Dis. 1979;38:39-45
39. Popert AJ,Gill AJ,Laird SM.A prospective study of Reiter’s syndrome. An interim report on the first 82 cases.Br J Vener Dis. 1964;40:160-165
40. Hannu T,Nieminen MS,Swan H, et al.Cardiac findings of reactive arthritis: an observational echocardiographic study.Rheumatol Int. 2002;21:169-172
41. Konttinen YT,Bergroth V,Nordström D, et al.IgA nephropathy in reactive arthritis.J Rheumatol. 1987;14:1070-1071
42. Khan MA.Update on spondyloarthropathies.Ann Intern Med. 2002;136:896-907
43. http://www.iusti.org/regions/Europe/euroguidelines.htm.
44. http://www.bashh.org/guidelines.
45. http://www.cdc.gov/std/.
46. Combe B,Landewe R,Lukas C, et al.EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Ann Rheum Dis. 2007;66:34-45
47. van de Heijde D,Landewé R.Imaging in spondylitis.Curr Opin Rheumatol. 2005;17:413-417
48. Balint PV,Kane D,Wilson H, et al.Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy.Ann Rheum Dis. 2002;61:905-910
49. Nikkari S,Puolakkainen M,Närvänen A, et al.Use of a peptide based enzyme immunoassay in diagnosis of Chlamydia trachomatis triggered reactive arthritis.J Rheumatol. 2001;28:2487-2493
50. Frydén A,Bengtsson A,Foberg U, et al.Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study.Br Med J. 1990;301:1299-1302
51. Bardin T,Enel C,Cornelis F, et al.Antibiotic treatment of venereal disease and Reiter’s syndrome in a Greenland population.Arthr Rheum. 1992;35:190-194
52. Toivanen A,Toivanen P.Epidemiological, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis.Curr Opin Rheumatol. 1995;7:279-283
53. Cuellar ML,Espinoza LR.Management of spondyloarthropathies.Curr Opin Rheumatol. 1996;8:288-295
54. Leirisalo-Repo M.Prognosis, course of disease, and treatment of the spondyloarthropathies.Rheum Dis Clin North Am. 1998;24:737-751
55. Anandarajah A,Ritchlin CT.Treatment update on spondyloarthropathy.Curr Opin Rheumatol. 2005;17:247-256
56. Patrono CRheumatology. 5th ed. Philadelphia: Mosby Elsevier, 2011. Section 4: Principles of management, vol. 50, pp.485–493.Hochberg MCSilman AJSmolen JSWeinblatt MEWeisman MH, ed. Philadelphia: Mosby Elsevier; 2011:
57. Juvakoski T,Lassus A.A double-blind cross-over evaluation of ketoprofen and indomethacin in Reiter’s disease.Scand J Rheumatol. 1982;11:106-108
58. Dougados M,Nguyen M,Caporal R, et al.Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study.Scand J Rheumatol. 1994;23:243-248
59. Wienecke T and Gotzsche PC. Paracetamol versus non steroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No: CD003789.
60. McGettigan P,Henry D.Cardiovascular risk and inhibition of cyclooxygenase.JAMA. 2006;296:1633-1644
61. Kearney PM,Baigent C,Godwin J, et al.Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.BMJ. 2006;332:1302-1302
62. Ray WA,Varas-Lorenzo C,Chung CP, et al.Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.Circ Cardiovasc Qual Outcomes. 2009;2:155-163
63. http://www.mhra.gov.uk.
64. http://nice.org.uk/guidance.
65. Palazzi C,Olivieri I,D'Amico E, et al.Management of reactive arthritis.Expert Opin Pharmacother. 2004;5:61-70
66. Blyth T,Hunter JA,Stirling A.Pain relief in the rheumatoid knee after steroid injection a single-blind comparison of hydrocortisone succinate, and triamcinolone acetonide or hexacetonide.Br J Rheumatol. 1994;33:461-463
67. Canoso JJ,Naredo ERheumatology. 5th ed. Philadelphia: Mosby Elsevier, 2011. Section 4: Principles of management, vol. 66, pp.617–628.Hochberg MCSilman AJSmolen JSWeinblatt ME, ed. Philadelphia: Mosby Elsevier; 2011:
68. Calin A.Management of Reiter’s syndrome.Ann Rheum Dis. 1979;38:96-97
69. Günaydin I,Pereira PL,Daikeler T, et al.Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study.J Rheumatol. 2000;27:424-428
70. Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews 1998, Issue 2. Art No: CD000952.
71. Cranney A, Welch V, Adachi J, et al. Calcitonin for preventing and treating corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews 2000, Issue 1. Art. No: CD001983.
72. Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No: CD001347.
73. Dougados M,van der Linden S,Leirisalo-Repo M, et al.Sulfasalazine in the treatment of spondyloarthropathy: a randomized, multicenter, double-blind, placebo-controlled study.Arthr Rheum. 1995;38:618-627
74. Clegg DO,Reda DJ,Weisman MH, et al.Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter’s syndrome): a Department Of Veterans Affairs Cooperative Study.Arthr Rheum. 1996;39:2021-2027
75. Egsmose C,Hansen TM,Andersen LS, et al.Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial.Ann Rheum Dis. 1997;56:32-36
76. Clegg DO,Reda DJ,Abdellatif M.Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs Cooperative Study.Arthr Rheum. 1999;42:2325-2329
77. Braun J,Zochling J,Baraliakos X, et al.Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial.Ann Rheum Dis. 2006;65:1147-1153
78. Owen ET,Cohen ML.Methotrexate in Reiter’s disease.Ann Rheum Dis. 1979;38:48-50
79. Calin A.A placebo controlled, crossover study of azathioprine in Reiter’s syndrome.Ann Rheum Dis. 1986;45:653-655
80. Lipsky PE,van der Heijde DM,St Clair EW, et al.Infliximab and methotrexate in the treatment of rheumatoid arthritis.N Engl J Med. 2000;343:1594-1602
81. Bathon JM,Martin RW,Fleischmann RM, et al.A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.N Engl J Med. 2000;343:1586-1593
82. Genovese MC,Bathon JM,Martin RW, et al.Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes.Arthritis Rheum. 2002;46:1443-1450
83. Reimold AM.New indications for treatment of chronic inflammation by TNF-(alpha) blockade.Am J Med Sci. 2003;325:75-92
84. Braun J,Brant J,Listing J, et al.Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.Lancet. 2002;359:1187-1193
85. Gorman JD,Sack KE,Davis JC.Treatment of ankylosing spondylitis by inhibition of tumour necrosis factor α.N Engl J Med. 2002;346:1349-1356
86. Braun J,Sieper J.Biological therapies in the spondyloarthritides – the current state.Rheumatology. 2004;43:1072-1084
87. van der Heijde D,Kivitz A,Schiff MH, et al.Efficacy and safety of adalimumab in ankylosing spondylitis: results of a multicenter, randomised, double-blind, placebo-controlled trial.Arthritis Rheum. 2006;54:2136-2146
88. Kavanaugh A,Tutuncu Z,Catalan-Sanchez T.Update on anti-tumor necrosis factor therapy in spondyloarthropathies including psoriatic arthritis.Curr Opin Rheumatol. 2006;18:347-353
89. Mease PJ,Goffe BS,Metz J, et al.Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.Lancet. 2000;356:385-390
90. Antoni CE,Krueger GG,de Vlam K, et al.Infliximab therapy improves symptoms and signs of psoriatic arthritis: results of the IMPACT 2 trial.Ann Rheum Dis. 2005;64:1150-1157
91. Mease PJ,Gladman DD,Ritchlin CT, et al.Adalimumab for the treatment of moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.Arthritis Rheum. 2005;52:3279-3289
92. Van der Bosch F,Kruithof E,Baeten D, et al.Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) versus placebo in active spondyloarthropathy.Arthritis Rheum. 2002;46:755-765
93. Kruithof E,De Rycke L,Roth J, et al.Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondyloarthropathies.Arthritis Rheum. 2005;52:3898-3909
94. Keane J,Gershon S,Wise RP, et al.Tuberculosis associated with infliximab, a tumour necrosis factor α-neutralising agent.N Engl J Med. 2001;345:1098-1104
95. Baeten D,Kruithof E,Van den Bosch F, et al.Systemic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?.Ann Rheum Dis. 2003;62:829-834
96. Mayer A,Chatelus E,Wendling D, et al.Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis.Arthritis Rheum. 2011;63:1274-1280
97. Flagg SD,Meador R,Hsia E, et al.Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial.Arthritis Rheum. 2005;53:613-617
98. Wechalekar MD,Rischmueller M,Whittle S, et al.Prolonged remission of chronic reactive arthritis treated with three infusions of infliximab.J Clin Rheumatol. 2010;16:79-80
99. Schafranski MD.Infliximab for reactive arthritis secondary to Chamydia trachomatis infection.Rheumatol Int. 2010;30:679-680
100. Kaipiainen-Seppänen O,Niinisalo H,Korpilähde T, et al.Treatment of reactive arthritis with infliximab.Scand J Rheumatol. 2003;32:122-124
101. Meador RJ,Hsia EC,Kitumnuaypong T, et al.Is etanercept (ENBREL) effective in the treatment of reactive and undifferentiated arthritis?.Arthritis Rheum. 2001;44:S348-S348
102. Gaylis N.Infliximab in the treatment of an HIV positive patient with Reiter's syndrome.J Rheumatol. 2003;30:407-411
103. Carter JD,Gerard HC,Hudson AP.Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum.Ann Rheum Dis. 2008;67:1181-1183
104. Nordström D,Lindy O,Lauhio A, et al.Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis.Rheumatol Int. 1998;17:175-180
105. Lauhio A,Leirisalo-Repo M,Lähdevirta J, et al.Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to chlamydia arthritis.Arthr Rheum. 1991;34:6-14
106. Sieper J,Fendler C,Laitka S, et al.No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study.Arthr Rheum. 1999;42:1386-1396
107. Yli-Kerttula T,Luukkainen R,Yli-Kerttula U, et al.Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis.Ann Rheum Dis. 2000;59:565-570
108. Kvien TK,Gaston JSH,Bardin T, et al.Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study.Ann Rheum Dis. 2004;63:1113-1119
109. Smieja M,MacPherson DW,Kean W, et al.Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis.Ann Rheum Dis. 2001;60:1088-1094
110. Wakefield D,McCluskey P,Verma M, et al.Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis.Arthr Rheum. 1999;42:1894-1897
111. Wollenhaupt J,Hammer M,Pott HG, et al.A double-blind, placebo-controlled comparison of 2 weeks versus 4 months treatment with doxycycline in chlamydia-induced reactive arthritis.Arthr Rheum. 1997;40:S143-S143
112. Putschky N,Pott H-G,Kuipers JG, et al.Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective double-blind trial.Ann Rheum Dis. 2006;65:1521-1524
113. Dreses-Werringloer U,Padubrin I,Zeidler H, et al.Effects of azithromycin and rifampicin on Chlamydia trachomatis infection in vitro.Antimicrob Agents Chemother. 2001;45:3001-3008
114. Carter JD,Valeriano J,Vasey FB.Doxycycline versus doxycycline and rifampicin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomised 9-month comparison.J Rheumatol. 2004;31:1973-1980
115. Carter JD,Espinoza LR,Inman RD, et al.Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: A double-blind, placebo-controlled, prospective trial.Arthritis Rheum. 2010;62:1298-1307
116. Leirisalo-Repo M,Paimela L,Julkunen H, et al.A 3-month, randomised, placebo-controlled study with combination antimicrobial therapy in acute reactive arthritis.Arthritis Rheum. 2001;44:S91-S91
117. Yli-Kerttula T,Luukkainen R,Yli-Kerttula U, et al.Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis.Ann Rheum Dis. 2003;62:880-884
118. Laasila K,Laasonen L,Leirisalo-Repo M.Antibiotic treatment and long term prognosis of reactive arthritis.Ann Rheum Dis. 2003;62:655-658
119. Pott HG,Wittenborg A,Junge-Hülsing G.Long-term antibiotic treatment in reactive arthritis.Lancet. 1988;1:245-256
120. Barber CE,Kim J,Inman RD, et al.Antibiotics for treatment of reactive arthritis: a systemic review and metaanalysis.J Rheumatol. 2013;40:916-928
121. Siva C, Tanjong GE, Zhou X, et al. Antibiotics for reactive arthritis. (Protocol). Cochrane Database Systematic Rev 2013; Issue 9. Art. No: CD006078.
122. O’Duffy EK,Clunie GPR,Lui D, et al.Double blind glucocorticoid controlled trial of samarium-153 particulate hydroxyapatite radiation synovectomy for chronic knee synovitis.Ann Rheum Dis. 1999;58:554-558
123. Pavlica L,Nikolic D,Magic Z, et al.Successful treatment of postvenereal reactive arthritis with synovectomy and 3 months' azithromycin.J Clin Rheumatol. 2005;11:257-263
124. Thiers BH.The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis.J Am Acad Dermatol. 1997;37:S69-S71
125. Louthrenoo W.Successful treatment of severe Reiter’s syndrome associated with human immunodeficiency virus infection with etretinate. Report of 2 cases.J Rheumatol. 1993;20:1243-1246
126. Rosenbaum JT,Smith JR.Anti-TNF therapy for eye involvement in spondyloarthropathy.Clin Exp Rheumatol. 2002;20 28:S143-S145
127. Braun J,Baraliakos X,Listing J, et al.Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with anti-tumor necrosis factor agents.Arthritis Rheum. 2005;52:2447-2451
128. Theodossiadis PG,Markomichelakis NN,Sfikakis PP.Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.Retina. 2007;27:399-413
129. Levy-Clarke G,Reed G,Nussenblatt R.Is anti-tumour necrosis factor (TNF) agents effective in reducing uveitis flares in patients with spondyloarthropathies?.Nature Clin Practice Rheumatol. 2007;3:376-377
130. Smith G,Roberts R,Hall C, et al.Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs.Br J Rheumatol. 1996;35:458-462
131. de Wit W,van Mourik I,Wiesenhaan PF.Prolonged maternal indomethacin therapy associated with oligohydramnios. Case reports.Br J Obstet Gynecol. 1988;95:303-305
132. http://www.bnf.org.